$19.89
1.27% yesterday
Nasdaq, Dec 08, 10:00 pm CET
ISIN
US8902604094
Symbol
TNXP

Tonix Pharmaceuticals Holding Corp. Stock price

$19.89
+3.05 18.11% 1M
-19.31 49.26% 6M
-13.09 39.69% YTD
+1.15 6.14% 1Y
-7,478.11 99.73% 3Y
-415,340.11 100.00% 5Y
-4,499,199,980.11 100.00% 10Y
-1,279,980.11 100.00% 20Y
Nasdaq, Closing price Mon, Dec 08 2025
+0.25 1.27%
ISIN
US8902604094
Symbol
TNXP
Industry

Key metrics

Basic
Market capitalization
$234.2m
Enterprise Value
$44.2m
Net debt
positive
Cash
$190.1m
Shares outstanding
10.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
22.7 | 20.2
EV/Sales
4.3 | 3.8
EV/FCF
negative
P/B
1.0
Financial Health
Equity Ratio
85.7%
Return on Equity
-93.2%
ROCE
-43.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$10.3m | $11.6m
EBITDA
$-98.0m | -
EBIT
$-99.9m | $-108.2m
Net Income
$-99.2m | $-136.2m
Free Cash Flow
$-76.3m
Growth (TTM | estimate)
Revenue
-8.8% | 14.8%
EBITDA
-24.9% | -
EBIT
-21.0% | -39.2%
Net Income
26.6% | -4.7%
Free Cash Flow
-10.3%
Margin (TTM | estimate)
Gross
34.3%
EBITDA
-951.2% | -
EBIT
-970.0%
Net
-963.4% | -1,175.5%
Free Cash Flow
-741.1%
More
EPS
$-11.1
FCF per Share
$-7.5
Short interest
16.0%
Employees
81
Rev per Employee
$120.0k
Show more

Is Tonix Pharmaceuticals Holding Corp. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Tonix Pharmaceuticals Holding Corp. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Tonix Pharmaceuticals Holding Corp. forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Tonix Pharmaceuticals Holding Corp. forecast:

Buy
88%
Hold
13%

Financial data from Tonix Pharmaceuticals Holding Corp.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
10 10
9% 9%
100%
- Direct Costs 6.77 6.77
24% 24%
66%
3.53 3.53
51% 51%
34%
- Selling and Administrative Expenses 68 68
87% 87%
656%
- Research and Development Expense 36 36
27% 27%
348%
-98 -98
25% 25%
-951%
- Depreciation and Amortization 1.93 1.93
54% 54%
19%
EBIT (Operating Income) EBIT -100 -100
21% 21%
-970%
Net Profit -99 -99
27% 27%
-963%

In millions USD.

Don't miss a Thing! We will send you all news about Tonix Pharmaceuticals Holding Corp. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tonix Pharmaceuticals Holding Corp. Stock News

Positive
Seeking Alpha
15 days ago
Tonix Pharmaceuticals Holding Corp. received FDA approval and launched Tonmya, the first new fibromyalgia drug in over 15 years. TNXP is expanding Tonmya into acute stress disorder [ASD] and major depressive disorder [MDD], with key phase 2 trials underway or planned to initiate. The company maintains a strong cash position, supporting operations into 2027, but future capital raises may be need...
Neutral
GlobeNewsWire
15 days ago
Tonix plans to initiate potential pivotal Phase 2 HORIZON study of TNX-102 SL in adults with major depressive disorder in mid-2026
Neutral
GlobeNewsWire
22 days ago
TONMYA is now available by prescription and available for pharmacy ordering nationwide TONMYA is the first FDA-approved treatment for fibromyalgia in more than 15 years TONMYA is a unique, non-opioid, once-daily bedtime analgesic that significantly reduces fibromyalgia pain and is generally well-tolerated CHATHAM, N.J., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasd...
More Tonix Pharmaceuticals Holding Corp. News

Company Profile

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.

Head office United States
CEO Seth Lederman
Employees 81
Founded 2007
Website www.tonixpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today